Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 20,598 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Completed Not applicable Interventional

A Peer-Led Intervention to Improve Postpartum Retention in HIV Care

NCT04168008
View directory record Official record
Conditions
HIV/AIDS
Interventions
WISH Adherence, WISH Parenting
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
16 Years and older · Female only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 1:21 AM EDT
Withdrawn Phase 3 Interventional

Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid

NCT04128176
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
Rituximab combined with Omalizumab
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 1Phase 2 Interventional

Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia

NCT00003874
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
monoclonal antibody CD19, monoclonal antibody CD20, in vitro-treated peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 29, 2011 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00718718
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CNTO 136 100 mg, CNTO 136 50 mg, CNTO 136 25 mg, Placebo, Methotrexate
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Aventura, Florida • Lexington, Kentucky • Frederick, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.

NCT00838058
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy Volunteers
Interventions
CE 224,535
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 14, 2009 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Not applicable Interventional

A Nutrition Intervention for Arthritis -3 (WCCR-ARTH3)

NCT03417648
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Plant-based diet, Supplement
Other
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years to 90 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts

NCT00368355
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Hemophagocytic Lymphohistiocytosis (HLH), Familial Hemophagocytic Lymphohistiocytosis (FLH), Viral-associated Hemophagocytic Syndrome (VAHS), X-linked Lymphoproliferative Disease (XLP)
Interventions
Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation, Stem Cell Infusion
Drug · Biological · Radiation + 1 more
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 55 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 20, 2026, 1:21 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV

NCT06557785
View directory record Official record
Conditions
HIV Infections
Interventions
CH505M5 N197D mRNA-gp160, CH505 TF mRNA-gp160
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 1 Interventional

Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma

NCT03168035
View directory record Official record
Conditions
Advanced Cancer, Lymphoma
Interventions
NC-4016
Drug
Lead sponsor
NanoCarrier Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 20, 2026, 1:21 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

NCT06564389
View directory record Official record
Conditions
Healthy Participants, Atopic Dermatitis
Interventions
PF-07832837, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
5
States / cities
Anaheim, California • San Diego, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Not applicable Interventional

Directly Observed Therapy for HIV Infected Adolescents

NCT00259389
View directory record Official record
Conditions
HIV Infections
Interventions
Directly observed therapy (DOT)
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 25 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 3 Interventional

Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients

NCT00005918
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz, Lamivudine, Stavudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
18
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

NCT00838591
View directory record Official record
Conditions
Asthma
Interventions
MN-221, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Loma Linda, California • San Diego, California • Sylmar, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 20, 2026, 1:21 AM EDT
Active, not recruiting Not applicable Interventional

Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma

NCT04478318
View directory record Official record
Conditions
Lung Neoplasm, Lymphoma, Melanoma, Fluorodeoxyglucose, Positron-emission Tomography
Interventions
uEXPLORER/mCT, mCT/uEXPLORER
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 20, 2026, 1:21 AM EDT
Terminated Phase 1 Interventional

Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693

NCT00493818
View directory record Official record
Conditions
Cancer
Interventions
GSK690693
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Indianapolis, Indiana • Detroit, Michigan • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

NCT04609878
View directory record Official record
Conditions
Asthma
Interventions
BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF pMDI 320/9 μg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
2,274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
107
States / cities
Saraland, Alabama • Phoenix, Arizona • Sun City West, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Retention in PrEP Care for African American MSM in Mississippi

NCT03256435
View directory record Official record
Conditions
Preventive Medicine, HIV Infections
Interventions
RAMP PrEP initiation, adherence, and retention intervention
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

NCT04281108
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 20, 2026, 1:21 AM EDT
Not listed Phase 3 Interventional

The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis

NCT03511625
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Acthar Injectable Product, Depo medrol
Drug
Lead sponsor
Attune Health Research, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 4 Interventional Results available

Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

NCT01126268
View directory record Official record
Conditions
Impetigo, Folliculitis, Secondarily Infected Eczema, Minor Soft Tissue Infections
Interventions
Retapamulin (Altabax)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
9 Months to 98 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 20, 2026, 1:21 AM EDT
Completed No phase listed Observational

Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

NCT02652091
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon beta-1b (Betaseron, BAY86-5046), BETACONNECT device
Drug · Device
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Cullman, Alabama • Boca Raton, Florida • New Port Richey, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Not applicable Interventional Results available

Improving Asthma Care by Partnering With School Nurses to Bring Asthma Care Into the Inner-City Schools

NCT02735174
View directory record Official record
Conditions
Asthma
Interventions
Sensor cap system for inhalers, App for SmartPhone, Motivational interviews, Telehealth clinic visits
Device · Other · Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 20, 2026, 1:21 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

NCT05963074
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Venetoclax
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
32
States / cities
Cerritos, California • Los Alamitos, California • San Luis Obispo, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Not applicable Interventional

Evaluation of Fats on Postprandial Glucose Control

NCT01869790
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Different fat types
Other
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 20, 2026, 1:21 AM EDT